| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/17460441.2015.1067198 |
| P698 | PubMed publication ID | 26372693 |
| P2093 | author name string | Xiaoli Wang | |
| Mengji Lu | |||
| Jing Hu | |||
| Jian Yin | |||
| Liying Qiu | |||
| Xiaopeng Zou | |||
| P2860 | cites work | Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran | Q24292781 |
| The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex | Q24316449 | ||
| Lipopolysaccharide endotoxins | Q24650970 | ||
| Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa | Q27645881 | ||
| Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial | Q28236008 | ||
| Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant | Q28384323 | ||
| Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant | Q30418297 | ||
| The polysaccharide inulin is characterized by an extensive series of periodic isoforms with varying biological actions | Q30655287 | ||
| Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. | Q30730983 | ||
| Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A. | Q33553810 | ||
| Design and synthesis of potent Quillaja saponin vaccine adjuvants | Q33645835 | ||
| An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses | Q33923199 | ||
| Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines | Q33933255 | ||
| Saponin-adjuvanted particulate vaccines for clinical use. | Q33999762 | ||
| Macrophagic myofasciitis: an emerging entity. Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Française contre les Myopathies (AFM). | Q34067293 | ||
| Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate | Q34099417 | ||
| Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome): clinical and immunological spectrum | Q34337165 | ||
| Vaccine adjuvants: current state and future trends | Q34358206 | ||
| Development of a minimal saponin vaccine adjuvant based on QS-21 | Q34433407 | ||
| New vaccine technology--what do you need to know? | Q34562376 | ||
| Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer | Q34565029 | ||
| Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial | Q34580726 | ||
| Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study | Q34621859 | ||
| Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations | Q34641666 | ||
| GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives | Q34655188 | ||
| Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial | Q34720308 | ||
| Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation | Q34920323 | ||
| Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity | Q35003701 | ||
| Delta inulin: a novel, immunologically active, stable packing structure comprising β-D-[2 -> 1] poly(fructo-furanosyl) α-D-glucose polymers | Q35020296 | ||
| Carbohydrate-based immune adjuvants | Q35054845 | ||
| Inulin-derived adjuvants efficiently promote both Th1 and Th2 immune responses | Q35953755 | ||
| Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant | Q36057500 | ||
| Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses | Q36106655 | ||
| Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probes | Q36216866 | ||
| Vaccine-induced th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset | Q36277359 | ||
| Achieving directed immunostimulating complexes incorporation | Q36530236 | ||
| Potentiation of photodynamic therapy of cancer by complement: the effect of gamma-inulin | Q36610512 | ||
| A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing | Q36711264 | ||
| New hepatitis B vaccine formulated with an improved adjuvant system | Q36780117 | ||
| Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer | Q36856279 | ||
| ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines | Q36968280 | ||
| Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine | Q37014879 | ||
| An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody | Q37123147 | ||
| Effect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigs | Q37173293 | ||
| Advances in saponin-based adjuvants | Q37390078 | ||
| Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems | Q37867102 | ||
| New pathways of protective and pathological host defense to mycobacteria | Q38025523 | ||
| Key roles of adjuvants in modern vaccines | Q38169040 | ||
| Adjuvants | Q39692526 | ||
| Natural and synthetic trehalose diesters as immunomodulators | Q39739655 | ||
| AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity | Q39782280 | ||
| Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage. | Q40107542 | ||
| Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. | Q40212724 | ||
| Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer | Q40444431 | ||
| Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma | Q40694541 | ||
| Adjuvants: current status, clinical perspectives and future prospects | Q40713020 | ||
| A gold glyco-nanoparticle carrying a Listeriolysin O peptide and formulated with Advax™ delta inulin adjuvant induces robust T-cell protection against listeria infection | Q41497431 | ||
| Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses | Q41626628 | ||
| A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human | Q41630579 | ||
| Immunotherapy of an ascitic rat hepatoma with cord factor (trehalose-6, 6'-dimycolate) and synthetic analogues | Q41831825 | ||
| Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells | Q42262934 | ||
| Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Aapi. | Q43211393 | ||
| Inulin glasses for the stabilization of therapeutic proteins | Q43543140 | ||
| Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection | Q43850828 | ||
| Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100. | Q44551911 | ||
| Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine | Q44674111 | ||
| Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin | Q45077886 | ||
| Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization. | Q45367139 | ||
| Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2. | Q45422511 | ||
| Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial | Q45552005 | ||
| Induction of homologous virus neutralizing antibodies in guinea-pigs immunized with two human immunodeficiency virus type 1 glycoprotein gp120-iscom preparations. A comparison with other adjuvant systems | Q45769167 | ||
| Effects of mycobacterial fractions and muramyl dipeptide on the resistance of mice to aerogenic influenza virus infection | Q45794933 | ||
| Development of soluble inulin microparticles as a potent and safe vaccine adjuvant and delivery system | Q46433891 | ||
| Vaccine adjuvant: it makes the difference | Q47356302 | ||
| Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. | Q47587014 | ||
| Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice | Q47854183 | ||
| Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells | Q47875310 | ||
| Local tolerance and systemic toxicity of single and repeated intramuscular administrations of two different formulations of the RTS,S malaria candidate vaccine in rabbits. | Q47896792 | ||
| Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. | Q47904576 | ||
| Synthesis of the potent immunostimulatory adjuvant QS-21A. | Q48004810 | ||
| A strong CD8+ T cell response is elicited using the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of ir | Q48005518 | ||
| Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination | Q49033611 | ||
| Monophosphoryl Lipid A (MPL) as an Adjuvant for Anti-Cancer Vaccines: Clinical Results | Q50047316 | ||
| Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant | Q50107849 | ||
| Immunobiological activities of nontoxic lipid A: enhancement of nonspecific resistance in combination with trehalose dimycolate against viral infection and adjuvant effects | Q50204124 | ||
| Nonclinical reproductive and developmental safety evaluation of the MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment. | Q50612774 | ||
| Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin. | Q51051582 | ||
| Evaluation of the intramuscular administration of Cervarix™ vaccine on fertility, pre- and post-natal development in rats. | Q51541633 | ||
| Pulcherrimasaponin, from the leaves of Calliandra pulcherrima, as adjuvant for immunization in the murine model of visceral leishmaniasis. | Q51820796 | ||
| A multistage tuberculosis vaccine that confers efficient protection before and after exposure. | Q54391413 | ||
| The mycobacterial cord factor adjuvant analogue trehalose-6,6'-dibehenate (TDB) activates the Nlrp3 inflammasome. | Q54488375 | ||
| Activation of protein kinase C by mycobacterial cord factor, trehalose 6-monomycolate, resulting in tumor necrosis factor-alpha release in mouse lung tissues. | Q55015081 | ||
| QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans | Q56447939 | ||
| Peptide vaccines derived from a malarial surface antigen: effects of dose and adjuvants on immunogenicity | Q57078116 | ||
| Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis | Q57268157 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1133-1144 | |
| P577 | publication date | 2015-09-15 | |
| P1433 | published in | Expert Opinion on Drug Discovery | Q5421204 |
| P1476 | title | Carbohydrate-based vaccine adjuvants - discovery and development | |
| P478 | volume | 10 |
| Q40093469 | Adjuvant formulations for virus-like particle (VLP) based vaccines |
| Q94465687 | Carbohydrate Conjugates in Vaccine Developments |
| Q28829361 | Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis |
| Q96123362 | Metabolic engineering for glycoglycerolipids production in E. coli: Tuning phosphatidic acid and UDP-glucose pathways |
| Q38780533 | Recent advances in synthetic carbohydrate-based human immunodeficiency virus vaccines |
| Q46243321 | Sensing Lipids with Mincle: Structure and Function |
Search more.